Importance of Clinical Trials Participation

Only about 5% of women with a gynecologic cancer participate in the dozens of clinical trials in gynecologic cancers. The predominant hope for improving on the treatment options for women diagnosed with a gynecologic cancer is through the conduct of clinical trials.

The Foundation for Women’s Cancer actively works with the Gynecologic Oncology Group (GOG) to encourage women to participate in clinical trials. Clinical trials are a crucial step in finding new and improved ways to improve treatment for women diagnosed with a gynecologic cancer.

Three examples of the important advances in the care of women as a result of clinical trials include:

  • Chemotherapy added to radiation improve cure rate in locally advanced cervical cancer (GOG 120, 109)
  • Platinum based chemotherapy plus paclitaxel is superior to platinum based chemotherapy plus cyclophosphamide (GOG 111)
  • IP therapy improves survival in subsets of women with newly diagnosed advanced ovarian cancer (GOG 172)

The patients that participated in the phase III clinical trials that led to these discoveries were among the first to benefit from these scientific advancements.

Spotlight

Check out this Women Magazine/aWomensheath.com page on gynecologic cancers, featuring our Listen, Learn, Act message and an article by National Race Surgeons Team Captain Linda Duska, M.D.

Awareness

This year’s GCAM awareness is focused on the important link between obesity and endometrial cancer. Check out the new toolkit to learn more.

Research

Prize applications are due on October 8, 2014. The Foundation for Women’s Cancer is pleased to share its 2014-2015 Research Grants and Awards booklet.

Education

The next Gynecologic Cancer Survivors Course will be Saturday, Oct. 11, 2014 in West Bloomfield, MI. For more information on educational events and courses, click here.